Researchers have found an easier way to screen for molecules that inhibit signaling pathways in cells. The new method uses light at both ends, so to speak, to activate a signaling pathway and then ...
A monthly overview of things you need to know as an architect or aspiring architect. Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with ...
Tumors shrank in 91% of taletrectinib-treated patients with advanced ROS1-positive NSCLC who were ROS1 TKI-naïve and 52% of those who were ROS1 TKI-pretreated in the study Responses were durable with ...
An expert explained what ROS1-positive non-small cell lung cancer is and why it is important to identify mutations like ROS1 through genetic sequencing. ROS1-positive non-small cell lung cancer, a ...
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced it has initiated an Expanded Access ...
Zidesamtinib achieved a 44% ORR and 1% CR rate in advanced ROS1-positive NSCLC patients previously treated with ROS1 TKIs. The ARROS-1 trial showed zidesamtinib's efficacy, especially in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback